InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (20 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
20
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the complete record of transactions filed by Obenshain Andrew, President of SGD. Insider active across 1 company, notably bluebird bio, Inc.. Cumulatively, 30 reports have been published. Breakdown: 0 buy · 20 sells. Total volume traded: €257k. Activity tracked since 3 May 2021. The latest transaction was disclosed on 3 March 2025 (Cession). Regulator: SEC (Form 4). All data is openly available.
Declarations30 total
921 shares@ US$3.91941.3% of flowCommon StockSEC:0001562180-25-002088:0
763 shares0Common StockSEC:0001562180-25-001152:0
86 shares@ US$7.39250.2% of flowCommon StockSEC:0001562180-25-000950:0
140 shares@ US$9.240.5% of flowCommon StockSEC:0001562180-25-000269:0
971 shares@ US$0.41730.1% of flowCommon StockSEC:0001562180-24-008362:0
130,000 shares0Common StockSEC:0001562180-24-007124:0
6,095 shares@ US$1.52763.2% of flowCommon StockSEC:0001562180-24-002306:0
1,879 shares@ US$0.90250.6% of flowCommon StockSEC:0001562180-24-001095:0
3,162 shares@ US$1.42941.6% of flowCommon StockSEC:0001562180-24-000363:0
807 shares@ US$3.16590.9% of flowCommon StockSEC:0001562180-23-007552:0
16,929 shares@ US$3.541620.5% of flowCommon StockSEC:0001562180-23-006277:0
67,600 shares0Common StockSEC:0001562180-23-002404:0
1,420 shares@ US$6.383.1% of flowCommon StockSEC:0001562180-23-000902:0
3,178 shares@ US$7.80438.7% of flowCommon StockSEC:0001562180-23-000409:0
1,263 shares@ US$6.41373.1% of flowCommon StockSEC:0001562180-22-007569:0
21,805 shares@ US$4.391435.2% of flowCommon StockSEC:0001562180-22-005942:0
18,000 shares0Common StockSEC:0001562180-22-001088:0
18,000 shares0Common StockSEC:0001562180-22-001088
852 shares@ US$9.244525.3% of flowCommon StockSEC:0001562180-22-000441
852 shares@ US$9.244512.5% of flowCommon StockSEC:0001562180-22-000441:0
832 shares@ US$10.179427.4% of flowCommon StockSEC:0001562180-21-007594
832 shares@ US$10.179413.5% of flowCommon StockSEC:0001562180-21-007594:0
586 shares0Common StockSEC:0001628280-21-023644:0
586 shares0Common StockSEC:0001628280-21-023644
100,000 shares0Common StockSEC:0001562180-21-005170:0
25 of 30 declarations
About Obenshain Andrew
Andrew Obenshain is the Chief Executive Officer of bluebird bio, Inc. He leads the company with a focus on innovation in gene therapies. His role includes overseeing operations and implementing strategies to achieve the company's objectives.
